Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora (COR)
NYSE:COR
Holding COR?
Track your performance easily
COR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$213.01 - $253.27
Previous Close$237.83
Volume1.74M
Average Volume (3M)1.24M
Market Cap
$45.97B
Enterprise Value$47.36B
Total Cash (Recent Filing)$3.13B
Total Debt (Recent Filing)$4.39B
Price to Earnings (P/E)31.6
Beta0.32
Next Earnings
Feb 05, 2025EPS Estimate
$3.49Last Dividend Ex-Date
Nov 15, 2024Dividend Yield0.89%
Share Statistics
EPS (TTM)7.50
Shares Outstanding193,280,140
10 Day Avg. Volume1,064,354
30 Day Avg. Volume1,244,984
Standard Deviation0.06
R-Squared0.18
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)71.21
Price to Sales (P/S)0.16
Price to Cash Flow (P/CF)11.50
P/FCF Ratio14.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda14.89
Forecast
1Y Price Target
$274.91Price Target Upside15.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Cencora News
PremiumCompany Announcements
Cencora Enhances Leadership with Strategic Acquisition
PremiumCompany Announcements
Cencora’s Strategic Acquisition and Financial Maneuvering
PremiumCompany Announcements
Cencora Raises $1.8 Billion for Strategic AcquisitionBulls Say, Bears Say
Bulls Say
Acquisition ImpactThe acquisition of Retina Consultants of America is expected to provide more near-term earnings contribution than initially estimated.
Financial PerformanceCencora closed its ~$4.5 billion acquisition of Retina Consultants of America, which is expected to significantly contribute to earnings per share.
Innovation And TechnologyCencora is leveraging innovation to create a more resilient supply chain through various technology solutions and partnership programs.
Bears Say
CompetitionCencora could face a headwind due to CI insourcing its new white-labeled Humira and Stelara biosimilars.
Financial PerformanceNet Cash from Operations of $1B was down from the prior year $1.83B.
International BusinessInternational Healthcare performance was weaker due to higher IT expenses in the European distribution business.
---
Ownership Overview
10.71% Insiders
27.76% Mutual Funds
0.12% Other Institutional Investors
37.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
COR FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was $213.01 and its highest was $253.27 in the past 12 months.
What is Cencora’s market cap?
Currently, no data Available
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Feb 05, 2025 which is in 26 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Nov 06, 2024. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.226 by $0.114.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 0.89%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is $3.49.
How many shares outstanding does Cencora have?
Cencora has 193,280,140 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $3.34 in its last earnings report, beating expectations of $3.226. Following the earnings report the stock price went up 4.866%.
Which hedge fund is a major shareholder of Cencora?
Among the largest hedge funds holding Cencora’s share is Bridgewater Associates, LP. It holds Cencora’s shares valued at 53M.
---
Cencora Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$274.91 (15.59% Upside)
$274.91 (15.59% Upside)
Blogger Sentiment
Bullish
COR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 366.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.05%
12-Months-Change
Fundamentals
Return on Equity
258.42%
Trailing 12-Months
Asset Growth
7.26%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. engages provision of pharmaceutical products and business solutions that improve access
to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical
Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic
pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded
sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and
health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate
site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and
includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.
---
COR Company Deck
---
COR Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Cencora showed strong financial performance with significant EPS and revenue growth, strategic acquisition to enhance service capabilities, and shareholder returns through increased dividends and share repurchases. However, challenges remain with goodwill impairment in PharmaLex and decreased margin pressures.Read More>---
COR Revenue Breakdown
87.62% Human Health
8.52% Alliance Healthcare
1.93% Other Healthcare Solutions
1.92% Animal Health
---
COR Stock 12 Month Forecast
Average Price Target
$274.91
▲(15.59% Upside)
Technical Analysis
Best Analysts Covering COR
1 Year
1 Year Success Rate
15/18 ratings generated profit
1 Year Average Return
+18.58%
reiterated a buy rating 2 months ago
Copying Kevin Caliendo's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +18.58% per trade.
---